- ADL-5859
-
- $97.00 / 5mg
-
2025-11-09
- CAS:850173-95-4
- Min. Order:
- Purity: 99.71%
- Supply Ability: 10g
- ADL-5859
-
- $0.00 / 1KG
-
2025-04-04
- CAS:850173-95-4
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1Ton
|
| | ADL-5859 Basic information |
| Product Name: | ADL-5859 | | Synonyms: | ADL5859 HCl;ADL5859 HCL;ADL5859; ADL 5859;ADL-5859;N,N-Diethyl-4-(5-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-4-yl)benzamide hydrochloride;ADL5859 hydrochloride;Benzamide, N,N-diethyl-4-(5-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-4-yl)-, hydrochloride (1:1);N,N-Diethyl-4-(5-hydroxyspiro[2H-1-benzopyran-2,4'-piperidin]-4-yl)benzamide hydrochloride ADL-5859;CS-24 | | CAS: | 850173-95-4 | | MF: | C24H29ClN2O3 | | MW: | 428.95166 | | EINECS: | | | Product Categories: | δ opioid receptor agonist.;API;Inhibitors | | Mol File: | 850173-95-4.mol |  |
| | ADL-5859 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≥21.45 mg/mL in DMSO; insoluble in EtOH; ≥5.48 mg/mL in H2O with ultrasonic | | form | solid | | color | White to off-white |
| | ADL-5859 Usage And Synthesis |
| Uses | N,?N-Diethyl-?4-?(5-?hydroxyspiro[2H-?1-?benzopyran-?2,?4''-?piperidin]?-?4-?yl)?-?benzamide Hydrochloride is a selective δ-opioid receptor agonist. It is an analgesic and antidepressive agent and a potential drug candidate for treating chronic pain. | | in vivo | ADL-5859 (0.3-10 mg/kg; p.o. once) hydrochloride reverses hyperalgesia in inflamed paw of rats and shows robust antidepressant-like activity[1].
1.19 Pharmacokinetic Properties of ADL-5859 in Rats and Dogs[1]. | Rats
IV 0.25 mg/kg and PO 3 mg/kg | Dogs
IV 1 mg/kg and PO 3 mg/kg | | CLs (L/h/kg) | 1.8±0.5 | 0.4±0.1 | | Vdss (L/kg) | 10.7±1.9 | 2.5±0.5 | | t1/2 (oral, h) | 5.3±0.7 | 4.7±0.2 | | F (%) | 33.4±3.2 | 66.5±6.8 |
| Animal Model: | Rats with Freund’s Complete Adjuvant (FCA) injection induced mechanical hyperalgesia[1] | | Dosage: | 0.3-10 mg/kg | | Administration: | Oral gavage; 0.3-10 mg/kg once | | Result: | Produced 100% reversal of hyperalgesia in the inflamed paw with a dose of 3 mg/kg and showed an oral ED50 value of 1.4 mg/kg.
|
| Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 0.3 and 3 mg/kg | | Administration: | Oral gavage; 0.3 and 3 mg/kg once | | Result: | Produced robust antidepressant-like activity in the rat forced swim assay with a dose of 3 mg/kg.
|
| | target | δ-opioid receptor | | IC 50 | δ Opioid Receptor/DOR |
| | ADL-5859 Preparation Products And Raw materials |
|